The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

Symic Biomedical gets $1.5m NIH Phase II SBIR grant to develop proteoglycan mimetic therapeutics.....           Celgene strengthens I&I portfolio with $7.2bn Receptos acquisition.....           FDA approves Boehringer and Lilly's Synjardy to treat type 2 diabetes in adults.....           Threshold begins Phase II trial tarloxotinib to treat head and neck or skin cancers.....           Biohaven begins dosing in Phase I trial with lead drug candidate BHV-0223.....           Allied-Bristol Life Sciences licenses Yale University's platform technology and lead molecules.....           Biolab to open new R&D centre in Greater Toronto Area.....           Sucampo launches tender to buy R-Tech Ueno for $278m.....           Audentes gets orphan status for At001 to treat XLMTM in US and Europe.....           Pfizer plots Ibrance expansion as early-stage breast cancer trial begins.....           Lilly, Boehringer amp up fight against Lantus with U.K. biosim launch.....           Impatient Horizon accuses Depomed of stalling its shareholder meeting plans.....           AbbVie scores one against FTC in pay-for-delay AndroGel suit.....           The FDA has spoken on biosimilar names. But will its hybrid proposal work?.....           On the heels of big production news, Novo Nordisk snaps up two diabetes drug developers.....           Novo Nordisk to invest $2bn in new manufacturing facilities in US and Denmark.....           Audentes gets orphan status for At001 to treat XLMTM in US and Europe.....           Alvogen to buy four pharmaceutical products from Pfizer for US market.....           Takeda to expand rights related to Nanotherapeutics? Vero cell technology platform.....           Corium gets US patent for MicroCor Transdermal System.....           Recipharm to manufacture RedHill's RHB-105 to treat H. pylori infection.....           Syndax, Genentech enter clinical trial collaboration in cancer immunotherapy.....           Oncolytics completes enrollment in randomized phase II NSCLC trial.....           NEJM publishes GSK's Phase IIIb/IV study of ambrisentan and tadalafil to treat PAH patients.....           Immatics, Anderson launch Immatics US to develop multiple T-cell and TCR-based adoptive cellular therapies.....           Enumeral, UMass Medical School enter into research study agreement.....           UPDATED: Novo to spend $1.2B, hire 700 for its first major drug plant in U.S......           Santen gets approval of TAPROS in China to treat open-angle glaucoma and ocular hypertension.....           CSL Behring gets marketing authorization for Respreeza in Europe.....           FDA gets orphan drug designation for Tocagen's Toca 511 & Toca FC to treat glioblastoma.....           FDA, EMA accept regulatory applications for Boehringer's Giotrif/Gilotrif to treat advanced squamous cell carcinoma of lung.....           Corium begins Phase I trial of Corplex Donepezil transdermal system to treat Alzheimer's disease.....           Eli Lilly pops the bubbly on U.S. Alimta patent victory.....           U.S. patent office puts new Copaxone's IP shield under the lens.....           White House urged to stop states' 'rationing' of hep C drugs.....           Mylan pursuit hasn't stopped Perrigo from scouting its own deals: CEO.....           Medivation has 'best-in-class' ambitions for newly purchased PARP inhibitor.....           UPDATED: Novo to spend $1.2B, hire 700 for its first major drug plant in U.S......           Amgen submits NDA for new intravenous calcimimetic etelcalcetide to treat SHPT in CKD patients.....           Oncodrone gets EUR2.5m Eurostars grant to develop prostate cancer drug OCD155.....           CSL Behring begins enrollment in Phase II/III trial of rVIIa-FP to treat hemophilia A or B.....           Arbutus begins dosing in Phase IIa expansion group trial of TKM-PLK1 to treat HCC.....           Mylan introduces Piperacillin and Tazobactam for injection in US.....           Shire to secure improved Cinryze manufacturing flexibility and capacity.....           Clementia enrols children in ongoing Phase II trial of palovarotene to treat FOP.....           Who should Allergan buy next? We asked, you answered.....           AstraZeneca, Peregrine partner on immuno-oncology combination trial to treat solid tumors.....           RetroSense's RST-001 gets FDA nod to start first-in-human clinical trials.....           Medivation to acquire worldwide rights of BioMarin's cancer drug talazoparib.....           Ironshore begins second Phase III trial of HLD-200 in pediatric ADHD patients.....           HSRx nears completion of OTC acne treatment trial of HSRx 2121.....           FDA expands use of Novartis' Promacta to include treatment for chronic ITP.....           FDA clears IND application of Biohaven's lead drug candidate BHV-0223.....           Allergan recalls specific lots of REFRESH Lacri-Lube, REFRESH P.M. 3.5g, FML 0.1%, and Blephamide in US.....           Accutest expands into Latin American countries to support drug development.....           Eisai reports positive Phase III trial results for FYCOMPA.....           Culturelle debuts only triple-action immune boosting supplement to include probiotics.....           Bristol-Myers, Sanofi catch a break in Plavix marketing case.....           Bass failed at challenging Acorda's patents. Can pharma rest easy now?.....           Shire rejigs manufacturing deal to step up Cinryze production.....           UPDATED: With vote approaching, Perrigo chief slams Mylan's 'troubling' values.....           Who should Allergan buy next? We asked, you answered.....           Stock slide makes biopharma deals more enticing for Gilead (and everyone else).....           Teva bows out of voting on Mylan's proposed deal for Perrigo.....           MTG Biotherapeutics gets FDA orphan drug status for MTG-201 to treat malignant mesothelioma.....           Pfizer reports positive topline results of two Phase III trials of Trumenba.....           Vital Therapies' Phase III trial of ELAD System in patients with AILD failed to meet primary endpoint.....           HedgePath launches clinical trial for proposed cancer treatment.....           EAS Consulting announces new senior advisor for OTC drugs and labeling services.....           DrugDev centralizes new SaaS solutions development for clinical research.....           Powerful cancer alliance joins cost-effectiveness drug crusade.....           Takeda takes unexpected blow as blockbuster Velcade patent ruled invalid.....           Analysts: Gilead's hep C scripts keep slowing, and Q3 sales forecasts should too.....           Pharma junkets for U.K. docs trigger tough new Sunshine rules, penalties.....           J&J uses share-the-wisdom approach to spread the word on Prezcobix.....           Allergan recalls eye drugs after patients complain of particles, blurred vision.....           Cellectar introduces PDC platform for targeted delivery of chemotherapeutics.....           Janssen submits extended MAA for paliperidone palmitate to EMA for schizophrenia treatment.....           Novartis buys remaining rights to GSK's cancer and MS drug ofatumumab for about $1bn.....           FDA grants rare pediatric disease designation for Sarepta's eteplirsen to treat DMD.....           Seres secures FDA orphan drug status for SER-109 to prevent recurrent CDI in adults.....           EMA accepts Takeda's MAA for ixazomib to treat relapsed/refractory multiple myeloma.....           Cellectar introduces PDC platform for targeted delivery of chemotherapeutics.....           Novartis shells out up to $1B to test GSK's Arzerra in MS.....           FDA accepts Allergan's Botox resubmission to treat lower limb spasticity in adults.....           Biota begins Phase I SAD trial of direct-acting antiviral BTA585.....           Majority in U.S. favor government steps to cut drug prices.....           Nervous drugmakers await decision on Bass' Ampyra patent challenge.....           Novartis shells out up to $1B to test GSK's Arzerra in MS.....           Lilly, Sanofi, Novo among many pharma players to throw off big price gains in H1.....           Ackman's Valeant ties pay off yet again with Sprout buy.....           EMA validates Pfizer's MAA for breast cancer combination treatment.....           Roche and Janus partner to develop TLR inhibitor for autoimmune diseases.....           Novartis' Odomzo gets approval in Europe to treat locally advanced basal cell carcinoma.....           Advaxis, MedImmune begin Phase I/II trial of combination drug to treat HPV-associated cancers.....           STA to market and distribute PharmaMar's cancer drug Aplidin in Australia and New Zealand.....           EnGeneIC begins Phase I tailored-EDV clinical trial in solid tumors.....           FDA grants QIDP designation to Vical's antifungal product candidate VL-2397.....           Valeant sizes up women's health with $1B deal for Sprout and its libido drug.....           Lilly faces patent-infringement fight over 'Take-n-Slide' drug adherence tool.....           In a first for diabetes, Lilly and Boehringer's Jardiance prevents heart attacks, strokes in trial.....           Lundbeck's big reorg will help fund R&D on new antipsychotic med.....           GSK OTC push marred by super-sized recall of toothpaste.....           UPDATED: FDA official encourages makers of Low T drugs to work together on a single risks trial.....           Valeant nears $1bn deal with Sprout for Libido drug Addyi.....           FDA grants rare pediatric disease designation for BioMarin's drisapersen to treat DMD.....           Cempra's solithromycin gets FDA fast track status to treat CABP.....           Madison begins dosing in prostate cancer trial of MVI-816 and pembrolizumab combination.....           Corbus gets FDA fast track status for Resunab to treat systemic sclerosis.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
Recent meetings

APS Industrial Insights
16 & 17 April 2015 - Sandwich

Exploring Opportunities within the Pharmaceutical Industry

Industrial Insights is a two day event allowing undergraduate and postgraduate students to explore opportunities within the pharmaceutical industry. The Academy of Pharmaceutical Sciences event, sponsored by Pfizer, AstraZeneca, GSK, Mylan and LGC saw more than 50 students visit Discovery Park, Kent for a series of talks by key people from across industry and academia. Attendees also enjoyed a tour of Pfizerís pharmaceutical research and manufacturing facilities, and had opportunities to network with pharmaceutical scientists, including with members of the New Scientist Focus Group (NSFG) and Students of the APS (SAPS).


APS Parkinson's Disease: From Patient to Product
19th May 2015 - Ware

A further meeting involving the APS and GSK took place on 19th May at the GSK Ware site to celebrate the 300th anniversary of GSKís Allen and Hanburys subsidiary.

This meeting focussed on Parkinsonís Disease and the opportunities pharmaceutical scientists have to improve the life of patients suffering from this terrible disease. The meeting featured presenters from the MHRA, Parkinsonís UK (the national charity), clinicians and pharmacists from academia and pharmaceutical scientists from industry.

A paper has been written from the output of this meeting, and we will notify once this is published.

Latest News
APS PharmSci 2015: Topical Innovation
The APS is pleased to announce a session on Tuesday 8th September 10:30 to 12:00, New developments in topical formulation including wound healing strategies which is being organised by the Skin Forum focus group.. This Skin Forum session addresses the twin challenges of innovation in topical skin therapies and formulation strategies to manage wounds. The two sessions will be delivered by industry leaders and practical examples of delivery options and best practice will be provided. . Objectives. Appreciate the differences between the intact skin barrier and wounds.. Understand the formulation options available for delivery of wound healing agents.. Gain an insight into innovation in topical skin formulations.. . The session will have two prominent speakers and the opportunity for two aspiring scientists chosen from the abstract submissions to present.. Dr Michael Herbig will present on Formulating for approval and commercialization. Implications for collaborations of industry with academia. Michael Herbig is the Head of Pharmaceutical Development at Almirall Hermal, Reinbek, Germany focusing on topical dermatological dosage forms. He studied pharmaceutical sciences at the University of Wuerzburg, Germany and obtained his PhD in drug delivery from the Swiss Federal Institute of Technology (ETH) in Zurich. Furthermore, he obtained an MBA for the Open University Business School, Milton Keynes, UK. . Michael started his professional career at Novartis, Basle, Switzerland where he held positions of increasing responsibility first in early development with focus on solid state characterization and bioavailability assessments as well as formulation feasibility studies for various dosage forms before moving into the pharmaceutical development of topical dosage forms. . He then moved to Almirall Hermal where he held the position of the group leader of formulation development before assuming his current position. In this role, his responsibilities range from formulation feasibility and technology assessments, galenical and analytical development to clinical trial supply and process development. In addition, he is a major contributor to the company's idea generation and innovation process. Next to this, he maintains academic collaborations in the fields of model development for skin penetration and stability optimization of emulsion systems.. Dr Mike Walker FRSB C Biol will present on New developments in formulations and devices for wound healing.. Mike Walker was first introduced to skin research in 1975, as part of his Biological Sciences degree course. This involved performing percutaneous absorption studies, for regulatory submission, as well as actively involved in evaluating dermal absorption of hazardous chemicals at the then Central Toxicology Laboratories at ICI, Alderley Park. In 1985 Mike was awarded a Master’s degree through Nottingham University and subsequently received his Doctorate in 1991 from Cardiff University. Both of these completed part-time whilst in full time employment.. Mike joined ConvaTec in 1988 to continue dermatological research before turning his attention to wound care after about ten years. He was subsequently elected as a Fellow of the Society of Biology in 2009 (now with Royal charter), and through 2003-2007 was awarded annual Innovation Awards for outstanding innovation and contribution, and a CEO award in 2011. Mike is presently a member of European Wound Management Association and have written over 50 scientific papers and contributed to several book chapters.
Science Cafe at PharmSci 2015
Are you interested in debating a scientifically relevant but somewhat controversial subject with your fellow scientists? The Science Café at the PharmSci conference each year provides such an opportunity and this year the topic will be:. “This House believes that the WHO must make vaccination against malaria compulsory for all children in Africa.” . Malaria is a devastating disease that affects millions of people, many of them children, in many parts of the world, but is a particular problem in developing countries. After years of scientific research, a vaccine has been developed and was recently approved by EMA, but a decision by WHO on whether to recommend its use is not due until later this year. Even though it may not be fully effective, it can be argued that even partial protection is better than none. Others may believe that a better understanding of the risk-benefit profile is necessary before the vaccine is widely used. What do you think?. On Tuesday 8 September at 08:15 (coffee and croissants provided!) the subject will be debated under the chairmanship of Colin Cable, with Prof. Yvonne Perrie supporting the motion and Prof. Donald Cairns opposing it. After opening statements, the floor will be open to all those present to express a view and attempt to sway the overall opinion.. What will be the outcome? What will be the deciding factors that influence opinion? Come along to the East Midlands Conference Centre in Nottingham to find out and to have your say. Remember: 08:15 on 8 September, and afterwards you can select from a range of sessions on a wide variety of scientific topics. Register today! . .
Two day Nanomedicines Event with Sessions on Wednesday 9th September at PharmSci 2015 followed by a meeting on Thursday 10th September Emerging nanomedicine applications in infection, cancer and CNS targeting at the EMCC, Nottingham.. If you are working in this exciting field or keen to find out more on recent development this is an opportunity not to be missed, to listen to key speakers from academia and industry and to actively participate in a workshop on the afternoon of Wednesday 9th September and to extend into latest development of nanotherapeutics for Infectious Diseases, Cancer and Neurodegenerative Diseases with an event on Thursday 10th September.. The nanomedicines stream organised jointly by the APS focus group on nanomedicine and by the British Society of nanomedicine (BSNM) will focus on clinical applications, formulation and challenges in manufacture and scale-up and emerging applications. . These sessions will take place at PharmSci 2015 on Wednesday 9th September with the nanotherapeutics event on Thursday 10th September. . On Wednesday 9th September . First session: “Nanomedicines and biotherapeutics”. This first session will focus on nanomedicines and their applications in clinical settings. The two speakers Andreas Schatzlein from UCL and Nanomerics and Chris Scott from Queens University Belfast will present some of their recent work in the area. Oral contributions from selected abstracts will conclude the session.. Second session: “Innovation in formulation, characterisation and delivery of nanomedicines”. The second session will explore the challenges involved in the characterisation of nanomedicines and new analytical tools used for this purpose. Two invited speakers will present their work: Jayne Lawrence (King's College, London) and Marianne Ashford (Astrazeneca). Oral contributions from selected abstracts will conclude the session.. Third session: BSNM workshop “Challenges for the scale up and manufacturing of nanomedicines”. The stream will be complemented in an afternoon with a workshop on the “challenges for the scale up and manufacturing of nanomedicines”. This session will give the opportunity to experts and to the audience to discuss these important aspects.. On Thursday 10th September- APS emerging nanomedicine applications in infection, cancer and CNS targeting. Joint Meeting with the British Society for Nanomedicine
APS Summer Student Placement for 2015
The APS is pleased to announce the first of the two summer student placements.. This is a new initiative for the APS who working with their focus groups were asked for their interest in participating in a pilot summer student placement scheme to submit a project proposal on a particular topic area they are interested in. A number of high quality proposals were reviewed and two were selected for this year.. . Emma Smith supervised by Dave Berry at Durham University and co-sponsored by the APS Material Science Focus Group. . . . The title of the project is: Comparing the physical properties of racemic and single enantiomer forms of pharmaceutical co-crystals and their glasses. The ambition of the project is to see if there are significant property differences with enantiomeric impurities in co-crystals and if these can be utilised to benefit overall efficiency in drug substance manufacture and efficacy in the drug product.. . The project will involve looking at the difference between bicalutamide R/S and S with some of its co-crystals (nicotinamide/ 2-hydroxybenzamide) to determine if any significant material property differences can be seen when using the racemate and single enantiomer of the drug, both in the crystalline state and in the glass. This will be done with ‘pure’ forms of the enantiomer/racemate as well as with mixtures of differing stoichiometry’s of each 25/75 R to S etc. . This initiative fits well with the APS strategy to raise opportunities for undergraduates and postgraduates, whilst promoting their scientific strategy. . The placement will run for 6-8 weeks and a poster presentation will be given by the student at the PharmSci 2015 meeting in Nottingham.
Follow us
Upcoming Events
APS 6th International PharmSci Conference 2015
7 - 9 September 2015
APS Emerging nanomedicine applications in infection, cancer and CNS targeting
10 September 2015
APS 20th Anniversary International Pharmaceutical Photostability Conference 2015
5 - 7 October 2015
MIBio 2015: Stability of biopharmaceuticals Ė From molecular interactions to successful products
21 October 2015
APS Stimulating antimicrobial innovation
22 October 2015
Job Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.